Humira and Byetta get expanded CHMP extensions go-ahead
This article was originally published in Scrip
Executive Summary
Abbott's Humira (adalimumab) is set to add ulcerative colitis to its roll call of inflammatory disease indications following a positive opinion from the EU's CHMP last week.